The global CAR T-cell therapy market size accounted for USD 12.88 billion in 2025 and is forecasted to hit around USD 128.55 billion by 2034, representing a CAGR of 29.10% from 2025 to 2034. The North America market size was estimated at USD 4.14 billion in 2024 and is expanding at a CAGR of 29.20% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: CAR T-Cell Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. CAR T-Cell Therapy Market, by Drug Type
8.1.1 Axicabtagene Ciloleucel
8.1.1.1. Market Revenue and Forecast
8.1.2. Tisagenlecleucel
8.1.2.1. Market Revenue and Forecast
8.1.3. Brexucabtagene Autoleucel
8.1.3.1. Market Revenue and Forecast
8.1.4. Others
8.1.4.1. Market Revenue and Forecast
9.1. CAR T-Cell Therapy Market, by Indication
9.1.1. Lymphoma
9.1.1.1. Market Revenue and Forecast
9.1.2. Acute Lymphocytic Leukemia
9.1.2.1. Market Revenue and Forecast
9.1.3. Chronic Lymphocytic Leukemia (CLL)
9.1.3.1. Market Revenue and Forecast
9.1.4. Multiple Myeloma (MM)
9.1.4.1. Market Revenue and Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Forecast
10.1. CAR T-Cell Therapy Market, by End User
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast
10.1.2. Cancer Treatment Centers
10.1.2.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type
11.1.2. Market Revenue and Forecast, by Indication
11.1.3. Market Revenue and Forecast, by End User
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type
11.1.4.2. Market Revenue and Forecast, by Indication
11.1.4.3. Market Revenue and Forecast, by End User
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type
11.1.5.2. Market Revenue and Forecast, by Indication
11.1.5.3. Market Revenue and Forecast, by End User
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type
11.2.2. Market Revenue and Forecast, by Indication
11.2.3. Market Revenue and Forecast, by End User
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type
11.2.4.2. Market Revenue and Forecast, by Indication
11.2.4.3. Market Revenue and Forecast, by End User
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type
11.2.5.2. Market Revenue and Forecast, by Indication
11.2.5.3. Market Revenue and Forecast, by End User
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type
11.2.6.2. Market Revenue and Forecast, by Indication
11.2.6.3. Market Revenue and Forecast, by End User
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type
11.2.7.2. Market Revenue and Forecast, by Indication
11.2.7.3. Market Revenue and Forecast, by End User
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type
11.3.2. Market Revenue and Forecast, by Indication
11.3.3. Market Revenue and Forecast, by End User
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type
11.3.4.2. Market Revenue and Forecast, by Indication
11.3.4.3. Market Revenue and Forecast, by End User
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type
11.3.5.2. Market Revenue and Forecast, by Indication
11.3.5.3. Market Revenue and Forecast, by End User
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type
11.3.6.2. Market Revenue and Forecast, by Indication
11.3.6.3. Market Revenue and Forecast, by End User
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type
11.3.7.2. Market Revenue and Forecast, by Indication
11.3.7.3. Market Revenue and Forecast, by End User
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type
11.4.2. Market Revenue and Forecast, by Indication
11.4.3. Market Revenue and Forecast, by End User
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type
11.4.4.2. Market Revenue and Forecast, by Indication
11.4.4.3. Market Revenue and Forecast, by End User
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type
11.4.5.2. Market Revenue and Forecast, by Indication
11.4.5.3. Market Revenue and Forecast, by End User
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type
11.4.6.2. Market Revenue and Forecast, by Indication
11.4.6.3. Market Revenue and Forecast, by End User
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type
11.4.7.2. Market Revenue and Forecast, by Indication
11.4.7.3. Market Revenue and Forecast, by End User
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type
11.5.2. Market Revenue and Forecast, by Indication
11.5.3. Market Revenue and Forecast, by End User
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type
11.5.4.2. Market Revenue and Forecast, by Indication
11.5.4.3. Market Revenue and Forecast, by End User
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type
11.5.5.2. Market Revenue and Forecast, by Indication
11.5.5.3. Market Revenue and Forecast, by End User
12.1. Kolon TissueGene, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. JCR Pharmaceuticals Co., Ltd.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Kolon TissueGene, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. JCR Pharmaceuticals Co., Ltd.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. MEDIPOST
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. PHARMICELL Co., Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. ANTEROGEN. CO., LTD
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bristol-Myers Squibb Company
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Novartis AG
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Gilead Sciences, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample